Edwards Lifesciences (NYSE:EW) VP Daniel Lippis Sells 1,019 Shares

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 1,019 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $80.98, for a total transaction of $82,518.62. Following the sale, the vice president owned 33,934 shares in the company, valued at $2,747,975.32. This represents a 2.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Stock Up 0.1%

EW stock opened at $81.16 on Tuesday. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89. The company’s 50 day simple moving average is $81.59 and its 200-day simple moving average is $81.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. The firm has a market capitalization of $46.79 billion, a P/E ratio of 44.35, a P/E/G ratio of 2.11 and a beta of 0.95.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.54 billion. During the same quarter in the prior year, the firm earned $0.59 EPS. The firm’s revenue was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Robert W. Baird set a $90.00 price target on Edwards Lifesciences in a report on Monday, January 12th. JPMorgan Chase & Co. upgraded Edwards Lifesciences from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $90.00 to $100.00 in a report on Thursday, December 18th. UBS Group reiterated a “neutral” rating and set a $94.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Wells Fargo & Company boosted their price objective on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Finally, Evercore reaffirmed an “outperform” rating and set a $94.00 price objective on shares of Edwards Lifesciences in a research report on Monday, January 5th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.96.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. MV Capital Management Inc. bought a new stake in Edwards Lifesciences in the fourth quarter worth approximately $26,000. Kemnay Advisory Services Inc. bought a new stake in Edwards Lifesciences in the fourth quarter worth approximately $27,000. JPL Wealth Management LLC bought a new stake in Edwards Lifesciences in the third quarter worth approximately $25,000. Hilton Head Capital Partners LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $28,000. Finally, Kohmann Bosshard Financial Services LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $28,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.